This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that…

Recurrent Langerhans Cell HistiocytosisRefractory Langerhans Cell Histiocytosis

~Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05828069

Phase 1

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications …

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more

~Estimated

~$10 – $6,250

Mayo ClinicNCT06712810